Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III

New data from Newron Pharmaceuticals’ Phase II study 014/015 showed that its investigational drug evenamide elicits sustained and significant symptom improvements in patients with treatment-resistant schizophrenia, the company announced Monday.